Oncopeptides Chief Financial Officer Henrik Bergentoft takes office today
November 13, 2023
German price of Pepaxti published
October 30, 2023
Oncopeptides recently successfully agreed on a reimbursed price for Pepaxti in Germany that in the company´s view reflects the innovation of the drug and is in line with the company´s financial projections.
Update on Oncopeptides’ appeal of U.S. withdrawal
October 3, 2023
On Monday, October 2, Oncopeptides participated in a joint meeting with the Center for Drug Evaluation and Research’s (CDER’s) hosted by Dr. Peter Marks. The meeting presented an opportunity for both parties to present their view on the issue. The materials used, including meeting notes, will be posted in the public docket in the future, we don´t have information on when.
Oncopeptides announces successful price negotiations for Pepaxti in Germany
September 26, 2023
Oncopeptides announces that following negotiations between Oncopeptides and the German Federal Joint Committee National Association of Statutory Health Insurance Funds (GKV-Spitzenverband), a reimbursed price for Pepaxti has been agreed on in Germany. The negotiated reimbursed price in Germany, which will also guide negotiations in other European markets, is reflective of the innovation Pepaxti brings to the market, and in line with the company´s financial projections.